<DOC>
	<DOCNO>NCT00062933</DOCNO>
	<brief_summary>Ocular melanoma , cancer eye , rare form cancer spread liver . A tumor liver , size location , sometimes remove surgery . The purpose study determine whether chemotherapy deliver liver , call isolate hepatic perfusion ( IHP ) , follow systemic ( whole body ) chemotherapy improve ability treat cancer . Study participant must 18 year old ocular melanoma spread liver . Before enrol study , undergo follow evaluation : physical exam ; x-ray ; blood test ; electrocardiogram ; compute tomography ( CT ) scan chest , abdomen pelvis ; magnetic resonance imaging ( MRI ) scan liver . The study include 15-minute quality-of-life questionnaire . Participants complete questionnaire 7 time period 2 year help investigator gauge health status progress . A laparotomy do , allow surgeon view tumor liver small incision abdomen patient general anesthesia . Sometimes tumor spread outside liver way see pre-operative scan . When happen , participant ineligible continue study , since important part treatment give liver . If laparotomy reveals participant eligible remainder study , participant receive IHP treatment surgery . Plastic tube call catheter place vein artery feed drain liver . This create separate blood supply liver alone . Heated chemotherapy give liver blood supply one hour , carefully keep rest body . After recover surgery , eligible participant receive systemic chemotherapy call temozolomide one year . This chemotherapy take mouth capsule form . Participants ask return NIH 10-11 time first year evaluate progress .</brief_summary>
	<brief_title>A Phase II Study Isolated Hepatic Perfusion ( IHP ) Patients With Ocular Melanoma</brief_title>
	<detailed_description>Patients unresectable hepatic metastasis secondary ocular melanoma undergo 60 minute hyperthermic isolate hepatic perfusion 1.5mg/kg melphalan follow one year oral temozolomide . Response treatment , duration response , pattern failure , survival , quality life end-points follow .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>INCLUSION CRITERIA : Histologically cytologically proven measurable metastatic ocular melanoma confine liver . Patients limited site extrahepatic disease dominant lifelimiting disease liver consider eligible extrahepatic site treat local ablative measure resection external beam radiation therapy . Patients limited extrahepatic disease undergo IHP treatment extrahepatic disease sequence determine clinical presentation patient disease treat prior initiate temozolomide therapy . Patients must chemotherapy , radiotherapy , biologic therapy malignancy 28 day prior liver perfusion must recover side effect except outline appendix III . Patients must ECOG performance standard 0,1 2 prior onstudy day prior treatment IHP . Patients must adequate hepatic function evidence bilirubin less 2.0 mg/dL PT equal 2 second upper normal limit AST/ALT le equal 10 time ULN . Patients must 18 year age great must great 30 kg , reason outline Section 6.2 . Patients must platelet count great 75,000 , HCT great 27.0 , ANC great equal 1,500/ul , creatinine le equal 1.5 mg/dL unless measure creatinine clearance great 60 mL/min/1.73 ( 2 ) . Patients must aware neoplastic nature his/her illness , experimental nature therapy , alternative treatment , potential benefit , risk . The patient must willing sign inform consent . EXCLUSION CRITERIA : Pregnant patient nurse mother exclude due unknown effect melphalan fetus newborn . Patients take immunosuppressive drug chronic anticoagulation eligible . Patients active systemic infection eligible . Patients biopsy proven cirrhosis evidence significant portal hypertension history , endoscopy , radiologic study exclude . Patients history congestive heart failure LVEF le 40 % exclude . Patients COPD chronic pulmonary disease PFT 's less 50 % predict age exclude . Patients history diagnosis venoocclusive disease ( VOD ) exclude . Patients chronic active hepatitis base positive serology test surface antigen B C exclude evidence cirrhosis pathology . If pathology specimen exist evidence cirrhosis determine base radiological study physical examination . If indication patient register study biopsy obtain time laparotomy IHP expectation occult clinically significant cirrhosis unlikely . If cirrhosis pathologically confirm patient undergo treastment take study . Patients radiographic sign cirrhosis undergo percutaneous biopsy prior registration . Patients prior hypersensitivity reaction melphalan , dacarbazine , temozolomide ineligible study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Clinical Response</keyword>
	<keyword>Duration Response</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Hyperthermia</keyword>
	<keyword>Survival</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Ocular Melanoma</keyword>
	<keyword>Eye Cancer</keyword>
</DOC>